Keywords: ایبوتینیب; Ibrutinib; Mathematical models; Clonal architecture; Venetoclax; CLL; Therapy resistance;
مقالات ISI ایبوتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ایبوتینیب; Mantle cell lymphoma; Geriatric assessment; Chemotherapy; Ibrutinib; Rituximab; Bendamustine; Lymphoma;
Keywords: ایبوتینیب; Follicular lymphoma; Treatment; Obinutuzumab; Idelalisib; Ibrutinib; Venetoclax; Lenalidomide;
Keywords: ایبوتینیب; Mantle cell lymphoma; Ibrutinib; Novel therapies; Bruton's tyrosine kinase inhibitors; Bortezomib; Lenalidomide; Relapsed; Refractory; Ibrutinib combinations;
Keywords: ایبوتینیب; Chronic lymphocytic leukemia; CLL; Ibrutinib; Idelalisib; Venetoclax; Targeted therapy;
Keywords: ایبوتینیب; Chronic lymphocytic leukemia; Cost-effectiveness; Ibrutinib; Markov model; Obinutizumab;
Keywords: ایبوتینیب; ventricular storm; dysrhythmia; electrical storm; torsades des pointes; ibrutinib; tyrosine kinase inhibitor;
Keywords: ایبوتینیب; Bortezomib; BTK; Clinical trial; Copanlisib; Ibritumomab tiuxetan; Ibrutinib; Idelalisib; Lenalidomide; Marginal zone lymphoma; Obinutuzumab; PI3K; Radioimmunotherapy; Rituximab; TGR-1202; Ublituximab; Venetoclax;
Keywords: ایبوتینیب; Bendamustine; CLL; Ibrutinib; Idelalisib; Obinutuzumab; Venetoclax;
Keywords: ایبوتینیب; Rituximab; Ibrutinib; Bortezomib; Carfilzomib; Fludarabine;
Keywords: ایبوتینیب; Waldenstrom macroglobulinemia; MYD88; Deubiquitinating enzymes; Ibrutinib; Proteasome;
Keywords: ایبوتینیب; Mantle cell; Stem cell transplantation; Maintenance; MRD; Novel therapies; Bortezomib; Ibrutinib; Lenalidomide;
Keywords: ایبوتینیب; Alemtuzumab; Ibrutinib; Idelalisib; Obinutuzumab; Ofatumumab; Rituximab;
Keywords: ایبوتینیب; ABT-199; delecja 17p; ibrutinib; idelalisib; przewlekła białaczka limfocytowa; wiek biologicznyABT-199; 17p deletion; Ibrutinib; Idelalisib; Chronic lymphocytic leukemia; Biological age
Keywords: ایبوتینیب; Hairy cell leukemia; HCL; Microenvironment; B cell receptor; BCR; BTK; Ibrutinib;
Keywords: ایبوتینیب; Mantle cell lymphoma; Relapsed/refractory; Bendamustine; Bortezomib; Ibrutinib; Autologous hematopoietic cell transplant; Allogeneic hematopoietic cell transplantation;
Keywords: ایبوتینیب; Chronic lymphocytic leukemia; Duvelisib; Ibrutinib; Idelalisib; Monoclonal antibodies; Obinutuzumab; Small molecule inhibitors; Venetoclax;
Keywords: ایبوتینیب; ABT-199; Ibrutinib; Idelalisib; Obinutuzumab; Otlertuzumab; CART; ABT-199; Ibrutinib; Idelalisib; Obinutuzumab; Otlertuzumab; CART;
Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry
Keywords: ایبوتینیب; BTK; Bruton's tyrosine kinase; CGS; cysteinylglycine dipeptide; CYS; cysteine (amino acid); DHI; dihydrodiol-ibrutinib; DHP-I; dihydropeptidase-I; DMSO; dimethyl sulfoxide; GLU; glutamate (amino acid); GSH; glutathione tripeptide; GST; glutathione-S-trans
Characterization of the binding of a novel antitumor drug ibrutinib with human serum albumin: Insights from spectroscopic, calorimetric and docking studies
Keywords: ایبوتینیب; Ibrutinib; Human serum albumin; Fluorescence spectroscopy; Isothermal titration calorimetry; Molecular docking;
Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies
Keywords: ایبوتینیب; Allogeneic hematopoietic cell transplantation; CLL; Ibrutinib; Idelalisib; Venetoclax;
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia
Keywords: ایبوتینیب; Waldenström macroglobulinemia; BTK; Ibrutinib; Second-generation BTK inhibitors;
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
Keywords: ایبوتینیب; BCR-ABL kinase inhibitors; Ibrutinib; Idelalisib; Infection; Janus kinase inhibitors; mTOR inhibitors; Small-molecule inhibitors;
Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia
Keywords: ایبوتینیب; Chronic lymphocytic leukemia; Ibrutinib; HLA-DR; CLL cells; T cells;
Molecular characterization and function analysis of grouper (Epinephelus coioides) Bruton's tyrosine kinase BTK
Keywords: ایبوتینیب; Epinephelus coioides; Cryptocaryon irritans; BTK; Ibrutinib;
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid
Keywords: ایبوتینیب; Ibrutinib; Dihydrodiol-ibrutinib; LC-MS/MS; Cerebrospinal fluid; B-cell malignancies;
Analiza skutecznoÅci ibrutynibu w podgrupie chorych na przewlekÅÄ
biaÅaczkÄ limfocytowÄ
z delecjÄ
17p: badanie obserwacyjne Polskiej Grupy ds. Leczenia BiaÅaczek u DorosÅych (PALG)
Keywords: ایبوتینیب; inhibitor BTK; ibrutynib; przewlekÅa biaÅaczka limfocytowa; delecja 17p; BTK inhibitor; ibrutinib; chronic lymphocytic leukemia; 17p deletion;
Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison
Keywords: ایبوتینیب; Bendamustine; CLL; First line of treatment; Ibrutinib; Indirect comparison;
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
Keywords: ایبوتینیب; chronic lymphocytic leukemia; ibrutinib; idelalisib; ofatumumab; indirect treatment comparison;
Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase
Keywords: ایبوتینیب; IL-1; ibrutinib; Bruton tyrosine kinase; NLRP3; inflammasome; macrophage; X-linked agammaglobulinemia; Staphylococcus aureus; Muckle-Wells syndrome; inflammation; APC; Allophycocyanin; ASC; Apoptosis-associated speck-like protein containing a CARD; BMDM;
Front-line treatment of CLL in the era of novel agents
Keywords: ایبوتینیب; Chronic lymphocytic leukaemia; First-line; Bruton's kinase inhibitor; Ibrutinib; Elderly; PI3Kδ inhibitor; Idelalisib; Venetoclax;
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors
Keywords: ایبوتینیب; Ibrutinib; Bruton tirosine kinase; Solid tumors; Checkpoint inhibitors; Tumor microenvironment; TEC kinases;
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
Keywords: ایبوتینیب; Acalabrutinib; Alectinib; Brigatinib; Ceritinib; Crizotinib; Dabrafenib; Dasatinib; Erlotinib; Gefitinib; Ibrutinib; Imatinib; Lorlatinib; Nilotinib; Osimertinib; Rociletinib; Trametinib; Vemurafenib;
Further numerical analysis on the solubility of ibrutinib in ethanol + water mixtures at different temperatures
Keywords: ایبوتینیب; Ibrutinib; Ethanol + water mixtures; Jouyban-Acree model; Preferential solvation; IKBI;
Efficient bioreductive production of (S)-N-Boc-3-hydroxypiperidine using ketoreductase ChKRED03
Keywords: ایبوتینیب; (S)-N-Boc-3-hydroxypiperidine (PubChem CID: 1514399); N-Boc-piperidin-3-one (PubChem CID: 2756825); Carbonyl reductase; Ketoreductase; Asymmetric reduction; Ibrutinib; Chiral alcohol; Biocatalysis;
Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Keywords: ایبوتینیب; Allotransplantation; High-risk chronic lymphocytic leukemia; Ibrutinib; Idelasilib; Venetoclax
Rationnel et modalités de prescription de l'ibrutinib dans les hémopathies lymphoïdes B
Keywords: ایبوتینیب; Ibrutinib; Inhibiteur de BTK; Leucémie lymphoïde chronique; Lymphome à cellules du manteau; Macroglobulinémie de Waldenström; Ibrutinib; BTK inhibitor; Chronic lymphocytic leukemia; Mantle cell lymphoma; Waldenström's macroglobulinemia;
Current strategies to create tailored and risk-adapted therapies for CLL patients
Keywords: ایبوتینیب; CLL; Maintenance; MRD; Venetoclax (ABT-199); Ibrutinib; Idelalisib (CAL-101); Obinutuzumab (GA101); Ofatumumab;
Targeted therapies for CLL: Practical issues with the changing treatment paradigm
Keywords: ایبوتینیب; Targeted therapy; Chronic lymphocytic leukemia; Ibrutinib; Idelalisib; Obinutuzumab
Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2016 r – Raport Grupy Roboczej PTHiT i PALG-CLL
Keywords: ایبوتینیب; przewlekła białaczka limfocytowa; analogi puryn; chlorambucyl; przeciwciała monoklonalne; idelalizyb; ibrutynib; wenetoklaksChronic lymphocytic leukemia; Purine nucleoside analogs; Chlorambucil; Monoclonal antibodies; Idelalisib; Ibrutinib; Venetoclax
Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia
Keywords: ایبوتینیب; Ibrutinib; Lymphoplasmacytic lymphoma; MGUS; MYD88; WHIM syndrome;
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia
Keywords: ایبوتینیب; Chronic lymphocytic leukemia; B-cell receptor; Bruton's tyrosine kinase; ibrutinib;
Thermodynamics of solubility of ibrutinib in ethanol + water cosolvent mixtures at different temperatures
Keywords: ایبوتینیب; Correlation; Ethanol; Ibrutinib; Solubility; Thermodynamics;
Ibrutinib : applications cliniques et perspectives de développement dans les hémopathies malignes B
Keywords: ایبوتینیب; Ibrutinib; Hémopathies malignes B; Efficacité; Tolérance; Perspective; Ibrutinib; B-cell malignancies; Efficacy; Toxicities;
Solubility and thermodynamic function of a new anticancer drug ibrutinib in 2-(2-ethoxyethoxy)ethanol + water mixtures at different temperatures
Keywords: ایبوتینیب; Apelblat model; Ibrutinib; Solubility; Thermodynamics; Van't Hoff model; Yalkowsky model;
Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic study
Keywords: ایبوتینیب; Ibrutinib; PCI-45227; Lenalidomide; Plasma; LC-MS/MS;
The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss
Keywords: ایبوتینیب; Osteoclast; Btk; Ibrutinib; Osteoporosis; Inflammatory bone destruction;
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB
Keywords: ایبوتینیب; BAFF; B cell-activating factor; BTK; Bruton's tyrosine kinase; CLL; chronic lymphocytic leukaemia; FLIP; FLICE (caspase-8)-like inhibitory protein; ibrutinib; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-o
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
Keywords: ایبوتینیب; Mantle cell lymphoma; BCR signaling pathway; Bruton tyrosine kinase (BTK); Ibrutinib;
Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia
Keywords: ایبوتینیب; B-cell receptor inhibitor; Bruton tyrosine kinase inhibitor; Ibrutinib; PCI-32765; Chronic lymphocytic leukemia;